SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001434868

ESPR

Esperion Therapeutics, Inc.
—
Market cap$819.5M
12-mo target$3.20 (+0.6%)
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)19 New Institutional Positions23 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ESPR right now — valuation, ownership and activity at a glance.
Market Cap
$819.5M
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$359.4M
Inst. Activity
19 buys / 23 sells
Insider Activity
$0.00 buy / $342.7K sell
Insider Net $
-$342.7K
Social Sentiment
33° Cool
SEC Reports
16
Press Releases
4
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 4, 2026 SEC
Esperion Therapeutics won a favorable claim construction ruling in the Nexletol/Nexlizet ANDA litigation. The court adop
COURT-RULING — Impact 5/10
Sep 3, 2026 Event
ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. et al
Court ruling (njd) — Docket: 2:24-cv-05921
Aug 13, 2026 SEC
Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M) led by JPMorgan doublin
INST-CLUSTER — Impact 5/10
Aug 3, 2026 earnings_calendar
ESPR Q2 2026 Earnings Scheduled — 2026-08-03
Jul 23, 2026 SEC
Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. Th
15-12G — Impact 5/10
Jul 13, 2026 Insider
Koenig Sheldon L. disposed of 647,460 shares
President and CEO
Jul 13, 2026 Insider
Halladay Benjamin disposed of 200,000 shares
Chief Financial Officer
Jul 13, 2026 Insider
Hoffman Robert E. disposed of 85,153 shares
Director
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
May 4, 2026NeedhamDOWNGRADEHold 50%
May 1, 2026HC Wainwright & Co.DOWNGRADENeutral 43%
Mar 13, 2026CitizensMAINTAINMarket Outperform 38%
Mar 3, 2026NeedhamMAINTAINBuy 50%
Nov 25, 2025Piper SandlerINITIATEOverweight 54%
Sep 19, 2025HC Wainwright & Co.REITERATEBuy 43%
Jun 17, 2025HC Wainwright & Co.REITERATEBuy 43%
May 7, 2025NeedhamMAINTAINBuy 50%
Apr 25, 2025HC Wainwright & Co.REITERATEBuy 43%
Apr 25, 2025NeedhamREITERATEBuy 50%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026008120%
Aug 1, 2026008120%
Jul 1, 2026008120%
Jun 1, 2026008120%
May 1, 20263821079%
Apr 1, 20263821079%
Mar 1, 20263821079%
Feb 1, 20263821079%
Price targets
Where 3 covering analysts think ESPR trades over the next 12 months.
$3.20 +0.6% upside Hold
Current$3.18 Low$3.16 Median$3.16 High$3.28 3 analysts
$3.16$3.28
Analyst rating Hold· 3.0/5 as of Sep 10, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
2 mentions 0 bullish 2 bearish 0 neutral
Recent posts
pennystocks Bearish 4mo ago
Biotech Short Watchlist Today: IOVA, BDTX, ESPR, SANA, FATE, ALT
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 8 bullish, 3 bearish, 1 mixed, 4 neutral · avg impact 5.3/10.Plus 4 press releases.
BULLISHCOURT-RULING5/10
Esperion Therapeutics won a favorable claim construction ruling in the Nexletol/Nexlizet ANDA litiga
Sep 4, 2026
BEARISHINST-CLUSTER5/10
Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M) led
Aug 13, 2026
NEUTRAL15-12G5/10
Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effec
Jul 23, 2026
BEARISHEFFECT5/10
Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333
Jul 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 3, 2026
Enforcement
ESPERION THERAPEUTICS, INC. v. MICRO LABS USA, INC. et al
Court ruling (njd) — Docket: 2:24-cv-05921
Aug 3, 2026
earnings_calendar
ESPR Q2 2026 Earnings Scheduled — 2026-08-03
Jul 21, 2026
Clinical Trial
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Phase Phase 2 — COMPLETED
Jul 14, 2026
listing_status
Delisted: ESPR — removed from the Nasdaq symbol directory
Esperion Therapeutics, Inc. - Common Stock
Jul 14, 2026
trading_halt
Halt Resumed: ESPR — trading resumed after D (Security Deletion)
Halted 2026-07-10T23:50:00.000Z | Resumed 2026-07-14T04:00:01.000Z
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Next FY$0.26$0.09–$0.49222.6%-11.8%—$0.4B4
Current Q$-0.07$-0.07–$-0.07-250.0%+0.0%1↑ 0↓$0.1B1
Next Q$-0.04$-0.04–$-0.0475.0%+0.0%1↑ 0↓$0.1B1
Current FY$-0.21$-0.21–$-0.21-90.9%+0.0%1↑ 0↓$0.3B1
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.070—
7d ago$-0.070—
30d ago$-0.070—
60d ago$-0.070—
90d ago$-0.007-0.063
Institutional ownership
Which big funds own ESPR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $359.4M total value (114,211,805 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, GOLDMAN. Net selling activity: 23 institutions trimmed/exited vs 19 added.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.22,128,021$69.9M19.5%—
VANGUARD CAPITAL MANAGEMENT LLC11,427,437$36.1M10.0%—
GOLDMAN SACHS GROUP INC10,380,646$32.8M9.1%DOUBLED +330.7%
STATE STREET CORP7,276,249$23.0M6.4%—
TWO SIGMA INVESTMENTS, LP7,126,739$22.5M6.3%—
GEODE CAPITAL MANAGEMENT, LLC6,629,966$21.0M5.8%—
BALYASNY ASSET MANAGEMENT L.P.4,654,778$14.7M4.1%NEW
FMR LLC4,612,705$14.6M4.1%DOUBLED +1131.8%
UBS Group AG3,836,202$12.1M3.4%DOUBLED +1269.6%
ALLIANCEBERNSTEIN L.P.3,587,702$9.8M2.7%DOUBLED +1270.6%
Recent position changes
FundActionPrevCurrentChangeValue
GOLDMAN SACHS GROUP INCDOUBLED2,410,45410,380,646+330.7%$32.8M
BALYASNY ASSET MANAGEMENT L.P.NEW—4,654,778—$14.7M
FMR LLCDOUBLED374,4814,612,705+1131.8%$14.6M
ALLIANCEBERNSTEIN L.P.DOUBLED261,7603,587,702+1270.6%$9.8M
VANGUARD PORTFOLIO MANAGEMENT LLCTRIM3,532,5632,471,671-30.0%$7.8M
MILLENNIUM MANAGEMENT LLCDOUBLED604,3452,225,733+268.3%$7.0M
WASATCH ADVISORS LPNEAR_EXIT15,768,8971,930,185-87.8%$6.1M
LMR Partners LLPDOUBLED35,8591,607,177+4381.9%$5.1M
JPMORGAN CHASE & CODOUBLED685,6661,396,857+103.7%$4.4M
Bank of New York Mellon CorpADD555,177732,616+32.0%$2.3M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 47 transactions. Net -$342.7K — $0.00 bought, $342.7K sold.
DateInsiderTitleTypeSharesPriceValue
Jul 13, 2026Koenig Sheldon L.President and CEOD647,460——
Jul 13, 2026Halladay BenjaminChief Financial OfficerD200,000——
Jul 13, 2026Hoffman Robert E.DirectorD85,153——
Jul 13, 2026Hoffman Robert E.DirectorD40,000——
Jul 13, 2026Hoffman Robert E.DirectorD7,040——
Jul 13, 2026CARROLL J MARTINDirectorD177,523——
Jul 13, 2026CARROLL J MARTINDirectorD21,000——
Jul 13, 2026Looker BenjaminChief Legal OfficerD667,524——
Jul 13, 2026CARROLL J MARTINDirectorD32,500——
Jul 13, 2026CARROLL J MARTINDirectorD44,000——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ESPR.
Shares short
17,401,689
Settlement Jun 30, 2026
Change vs prior
-16.0%
Semi-monthly cycle
Days to cover
1.7
At avg daily volume
Of shares outstanding
≈6.8%
Estimate — not % of float
HaltedCodeReasonStatus
Jul 10, 2026T12Info RequestedNot resumed
Jul 10, 2026DDeletionResumed
All ESPR filing & press-release reports (20)